Strados Labs - Revolutionary E-Stethoscope for Remote Patient Monitoring | SOSV - The Accelerator VC

Strados Labs offers a remote respiratory monitoring system that provides automatic reports to doctors on unusual lung activity in patients. The company’s RESP product allows one respiratory professional to remotely monitor the conditions of at least 10x the number of patients that would otherwise be possible. RESP is able to provide continuous lung monitoring to determine which patients are getting worse and when. The system enables enhanced patient monitoring for overloaded hospitals, while also reducing patient and health care provider contact and exposure risk to COVID-19. The product is available now for research and on a compassionate use basis, with clinical trials at leading hospitals ongoing.

(00:00):
The standard way for a physician to listen to a patient with a stethoscope, actually last year celebrated its 200th anniversary. It makes tremendous sense not to have to listen to a patient's chest by being side by side, but rather to be able to do that remotely,
(00:17):
This is the device that we developed. So we've taken the idea of what a stethoscope is capable of doing, and we can make that so that it can be placed on the body. You sync it to a smartphone and we're able to start recording lung sounds from there and really we say be able to set it and forget it.
(00:34):
Strados Labs has created a revolutionary E-Stethoscope: RESP™. RESP enables continuous remote monitoring of lung sounds in hospital settings. And for outpatients, even hundreds of miles away.
(00:46):
We've seen over a 50% reduction in outpatient visits since COVID has started. We don't see that necessarily changing in the short run. And so this is a technology that enables care teams to still see patients remotely. And we integrate our devices over an existing telehealth platforms, so that it's really easy for these doctors to use.
(01:08):
And of course, with infectious diseases such as COVID-19, the last thing we want right now is for patients to be unnecessarily exposed to caregivers and for caregivers to be unnecessarily exposed to patients. And what we're learning with COVID is that you have to be very attuned to very sensitive changes. So if somebody goes from one cough per hour to two coughs per hour to four coughs per hour, they may be unaware that their signs are increasing, but the RESP, the device, instead of a little snapshot for 30 seconds twice a day, it gives the physician or clinician a 24 hour periodic view of how the patient's doing. And that's really important. Many of our clinicians describe this as the respiratory counterpart to Holter monitoring of the heart, and they see it as a very broadly usable and useful tool.
(02:06):
RESP enables enhanced patient monitoring for overloaded hospitals. It allows one person to remotely monitor more than 10 times the number of patients. This reduces patient-healthcare provider contact and COVID-19 exposure risk.
(02:21):
HAX has been an amazing partner of ours helping us with supply chain management, with the design and development of the product, spent a lot of time with them in the Shenzhen office last year to get this really to where it is today. And SOSV as well has been an amazing partner. They've understood at every step and every turn the need for a product like ours and particularly with respect to COVID, and have stepped up to help us, you know, make sure that we are capitalized and strategically ready to ramp up our products.

------------------
SOSV - The Accelerator VC

WHO WE ARE, WHAT WE DO, WHY WE DO IT

SOSV is a multi-stage venture capital investor. We run multiple world-class vertical accelerator programs, and provide seed, venture and growth stage follow-on investment into superstar companies. Our unique full-stack model has delivered a net IRR over the last 20 years that puts us in the top 10% of all venture funds worldwide.

SOSV provides intellectual and financial capital to accelerate founders’ big ideas for positive change. SOSV has funded over 900 startups to date. We currently fund over 150 startups per year through our programs: HAX (hardware and connected devices), IndieBio (life sciences), Chinaccelerator and MOX (cross-border internet and mobile in Asia), dlab (blockchain, data and decentralization), and Food-X (food innovation).

---